Core Viewpoint - Zhaoke Ophthalmology-B (06622.HK) experienced a significant stock price increase, rising 8.6% to HKD 3.41, marking a new high since October 13 and an overall increase of over 1.8 times in the year [1] Company Developments - Zhaoke Ophthalmology has entered into a distribution and supply agreement with leading Indonesian pharmaceutical company PT Ferron for the commercialization of BRIMOCHOL™PF in Indonesia, an innovative drug licensed from enpoint for the treatment of presbyopia [1] - Under the agreement, Zhaoke Ophthalmology grants PT Ferron exclusive rights to import, promote, distribute, market, and sell the product in Indonesia [1] - The company will receive an upfront payment and may earn additional milestone payments based on specific achievements [1]
港股异动丨兆科眼科盘中涨超8%创近一个月新高 与PT Ferron签订分销协议